Dr Mauro will oversee the company's clinical immuno-oncology programs
Advaxis has appointed Dr David J Mauro as executive vice president, chief medical officer. Dr Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs.
He most recently served as executive director, section head, Oncology Clinical Development at Merck & Co where he was involved in the strategic oversight and tactical implementation of clinical development and translational science for multiple programs within the oncology portfolio, including its recently approved PD-1 inhibitor, Keytruda (pembrolizumab).
"Dr Mauro brings a wealth of experience overseeing the design, conduct and management of clinical trials," said Mr Daniel J O'Connor, president and CEO, Advaxis. He added, "His expertise will be essential as we advance the clinical development of our proprietary Lm-LLO cancer immunotherapies and prepare to initiate multiple clinical trials in the coming months. We are proud to have Dr Mauro join our team and look forward to his contributions as Advaxis establishes its position among the leaders in cancer immunotherapy."
He will oversee the company's clinical programs, including the planned Phase 3 clinical trial in cervical cancer, the Phase I/II study with ADXS-HPV in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, and the Phase I/II study with ADXS-PSA in combination with Merck's approved PD-1 inhibitor, Keytruda, in metastatic, castration-resistant prostate cancer.
"I am excited to join Advaxis at such an important time in the Company's development. I look forward to managing the planned Phase 3 clinical trial in cervical cancer, as well as the early stage monotherapy and combination therapy trials. Overall, I believe there is great potential in the medical community for cancer immunotherapies, and I look forward to advancing Advaxis's unique technology," stated Dr Mauro.
